---
title: "Viking Therap | 10-Q: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284743489.md"
datetime: "2026-04-30T10:16:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284743489.md)
  - [en](https://longbridge.com/en/news/284743489.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284743489.md)
---

# Viking Therap | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -1.37, missing the estimate of USD -0.9952.

EBIT: As of FY2026 Q1, the actual value is USD -169.93 M.

Viking Therapeutics, Inc. operates as a single reportable segment, focusing on the development of novel therapies for metabolic and endocrine disorders, and has not generated any revenue since its inception.

#### Operational Metrics

-   **Net Loss**: The net loss for the three months ended March 31, 2026, was - $158,325 thousand, an increase from - $45,629 thousand for the same period in 2025.
-   **Comprehensive Loss**: The comprehensive loss was - $159,559 thousand for the three months ended March 31, 2026, compared to - $45,057 thousand for the prior year period.
-   **Research and Development (R&D) Expenses**: R&D expenses significantly increased by 262.8% to $150,150 thousand for the three months ended March 31, 2026, from $41,391 thousand in the comparable period of 2025, primarily due to higher expenses in clinical studies, manufacturing, consultants, salaries, and preclinical studies.
-   **General and Administrative (G&A) Expenses**: G&A expenses slightly decreased by -0.7% to $13,975 thousand for the three months ended March 31, 2026, from $14,078 thousand in the prior year period, mainly due to decreased legal and patent services and stock-based compensation.
-   **Interest Income, Net**: Net interest income decreased to $5,800 thousand for the three months ended March 31, 2026, from $9,864 thousand in the same period of 2025, primarily due to lower average cash balances.
-   **Accumulated Deficit**: The accumulated deficit grew to - $1,005,871 thousand as of March 31, 2026, from - $847,546 thousand as of December 31, 2025.

#### Cash Flow

-   **Net Cash Used in Operating Activities**: Cash used in operating activities was - $113,976 thousand for the three months ended March 31, 2026, compared to - $52,331 thousand for the same period in 2025, reflecting increased net losses and changes in working capital.
-   **Net Cash Provided by Investing Activities**: Cash provided by investing activities was $54,189 thousand for the three months ended March 31, 2026, down from $63,245 thousand in the prior year, primarily from proceeds from maturities of investments offset by purchases of investments.
-   **Net Cash Provided by Financing Activities**: Cash provided by financing activities increased significantly to $12,077 thousand for the three months ended March 31, 2026, from $349 thousand in 2025, driven by proceeds from an ATM Offering and stock option exercises.
-   **Cash and Cash Equivalents (End of Period)**: As of March 31, 2026, cash and cash equivalents totaled $118,116 thousand, a decrease from $165,810 thousand at December 31, 2025.

#### Strategic Summary and Outlook

Viking Therapeutics, Inc. is focused on advancing its clinical pipeline, including VK2735 for obesity (Phase 3 and Phase 2 trials) and VK2809 for NASH/MASH, with positive 52-week histologic data from the Phase 2b VOYAGE study. The company has secured multi-year manufacturing agreements for VK2735 API and finished product supply with CordenPharma, including dedicated capacity for over one billion oral tablets annually. As of March 31, 2026, Viking Therapeutics, Inc. had $603.0 million in cash, cash equivalents, and short-term investments, which is believed to be sufficient to fund operations through at least June 30, 2027, though additional capital will be required for future operations and clinical trials.

### Related Stocks

- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)

## Related News & Research

- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)
- [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md)
- [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md)